{"name":"Syntara","slug":"syntara","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Inhaled mannitol","genericName":"Inhaled mannitol","slug":"inhaled-mannitol","indication":"Cystic fibrosis","status":"phase_3"},{"name":"Aridol","genericName":"Aridol","slug":"aridol","indication":"Other","status":"marketed"},{"name":"Matching Placebo (B)","genericName":"Matching Placebo (B)","slug":"matching-placebo-b","indication":"Other","status":"phase_3"},{"name":"Placebo Comparator: Arm B - Control","genericName":"Placebo Comparator: Arm B - Control","slug":"placebo-comparator-arm-b-control","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Inhaled mannitol","genericName":"Inhaled mannitol","slug":"inhaled-mannitol","phase":"phase_3","mechanism":"Inhaled mannitol acts as an osmotic agent that draws fluid into the airways to hydrate secretions and improve mucociliary clearance.","indications":["Cystic fibrosis","Bronchiectasis"],"catalyst":""},{"name":"Aridol","genericName":"Aridol","slug":"aridol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Matching Placebo (B)","genericName":"Matching Placebo (B)","slug":"matching-placebo-b","phase":"phase_3","mechanism":"Matching Placebo (B) is a pharmacologically inert substance used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo Comparator: Arm B - Control","genericName":"Placebo Comparator: Arm B - Control","slug":"placebo-comparator-arm-b-control","phase":"phase_3","mechanism":"A placebo comparator arm provides no active therapeutic intervention and serves as a control baseline in clinical trials.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-11-28","type":"pipeline","source":"simplywall.st","summary":"Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPQXAtbnE4WUxOVmRoZ2phcHQ4VkNSS1NQVldSSXF4R2FQUHV0ZElBVUV4dTdiRVhQR2Z6TEZ3TEx6V1VFdHlLR09BcDZuNVJkT1pUX3RicnBDUjFkVDdkQV9XSVloQ08tdTBlZk9tVFRTTU1Sa2tBd1BHUllWdEhobWJSNWpXd3R0TzdvNXM2Ym5qcjYwSUZB?oc=5","date":"2024-11-26","type":"pipeline","source":"Livewire Markets","summary":"The ASX-listed Biotech set to unlock significant value - Hashan De Silva - Livewire Markets","headline":"The ASX-listed Biotech set to unlock significant value - Hashan De Silva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQOGRnMHJZbndvb1FISU5DQjFKUG9NVTc5cF9xNnBwN3dyOVo5bDNRWEdoaGZndjBRRG5mSzMwU2xwc2xpcUxhM0JYYmFBcFItWldRSjk3eVNKbTZiV3RHMXRNTHVad25HcFdmdXZiWFpTLXNMWVJ6RGh1LWVfNF8wLTZfR0xobXhnRUJmZV8tYUQyZ0JGUW91aEhtYTBNQzN5czJfcGstdmNYd3FKa1lR?oc=5","date":"2024-09-20","type":"pipeline","source":"AFR","summary":"The five pharma stocks exciting investors - AFR","headline":"The five pharma stocks exciting investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE81TERIOEQ3SVl3Z1ZhNFdNTDc3Rkg1M0F5ZXFabV8zNkNGbTNvUUxjX0lYWmhlYS1SdHdoNkctYVlmQTBfWXlUOE5BMTQ4VlQxUWVPYU01TUhETW1Jb1YtZUhNMklHYmdX?oc=5","date":"2023-12-12","type":"pipeline","source":"Proactive financial news","summary":"Syntara Ltd Share Price - SNT, RNS News, Articles, Quotes, & Charts (ASX:PXS) - Proactive financial news","headline":"Syntara Ltd Share Price - SNT, RNS News, Articles, Quotes, & Charts (ASX:PXS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE5jdHVqd0ZqQmktUF91RW15TUxOeXdmUVNqS2NpSkVEZnBHaVB2Zk02ZG5HN29XTUtYejBiMUhhbTVNZlVvVGdZZVB4SzlBZnJETEE?oc=5","date":"2023-12-08","type":"pipeline","source":"The Motley Fool Australia","summary":"Syntara Ltd (ASX: SNT) - The Motley Fool Australia","headline":"Syntara Ltd (ASX: SNT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNZ0NCWVJhZTF2bE85MmN5M0FtUE1iYXFTZWhYWVctMXVlc1cxcTJxaFpKR1ZpVnE2TnQ5Z1RjRnRMallxaGExMmU5Wjl3R1BMLUJpQ0lBczkyTHh0VmQ5eTBOdU5UaXhvY05BaS1lVElydkJtM0VQcmFfV25WTUpxM3NFTS12NDNQTzl6dk1qUEVzTmlYYkFPY1dpVlp5dHR5NE4zWkpuSXhpbHFYcFY3TjlVWGhYRHU5XzZpbnA2X0RtZ1ZJeHN5d2hLR01CVU5tLXRZQV9hNXhsa2JlY044aXFCZ1V4ZjhRbnctMF91Y09SQ2s4YzNUVQ?oc=5","date":"2023-10-18","type":"pipeline","source":"Proactive financial news","summary":"Pharmaxis finalises sale of MBU to Arna Pharma; shifts focus to blood-related cancer treatments - Proactive financial news","headline":"Pharmaxis finalises sale of MBU to Arna Pharma; shifts focus to blood-related cancer treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOcUpYYlZkYUhteWREQ1h3alZNZlRjb0cxa0VpcllEVS1qaGhnTjk1LUFxVmVHZDlIakowU3VDcHdsMXYtcGhoVHJhMjVha1NvSDl4QXoyX1dDTE5wYUw3aElncklCNkt0N1pyZzF6VEtTR3o2OGhucndCckZwVlRMMW9BMGFLRlZncEt5QlU2aDE3c1F2VXh3VC1YUE04b3oz?oc=5","date":"2023-10-03","type":"pipeline","source":"Biotech Dispatch","summary":"A name change and significant sale as Pharmaxis becomes Syntara - Biotech Dispatch","headline":"A name change and significant sale as Pharmaxis becomes Syntara","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPUm85RHhOZUZKMTVrVHdUYTczdEZYNmc4cVhUbkNpRnc0VGt2alpZSVFDN3g3VzQ3NzNNaXR1SUVwQUFiQ0Fyd2FMeFhXSUVJa0VuU2pLY3JwZjRHUkFMY2t0a0VqT0xfejN2RmRLbEJ6a2Q3RVFxNFZYT19rd0p4N1NlSGtCT0dUbDM1Ynh0Q1c0Q3BHNWhfeTVHbi1XQmlTMmFrZ3pCdWdJb3hGVFdTQ1A3VXJtVS1LaGZqVFJycHVNZXAzYTNaUE9sLVg5aWNtbWNkRWtSbGZVR3FvMWxDc0xtYTRTZDY1S0hpN2JTNmhuYnpGbzBienJ4VQ?oc=5","date":"2023-10-03","type":"pipeline","source":"Proactive financial news","summary":"Pharmaxis to undergo major company restructure and rebrand as Syntara; sells mannitol business - Proactive financial news","headline":"Pharmaxis to undergo major company restructure and rebrand as Syntara; sells mannitol business","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}